165 reports of this reaction
2.4% of all TOBRAMYCIN AND DEXAMETHASONE reports
#6 most reported adverse reaction
OCULAR HYPERAEMIA is the #6 most commonly reported adverse reaction for TOBRAMYCIN AND DEXAMETHASONE, manufactured by Novartis Pharmaceuticals Corporation. There are 165 FDA adverse event reports linking TOBRAMYCIN AND DEXAMETHASONE to OCULAR HYPERAEMIA. This represents approximately 2.4% of all 6,884 adverse event reports for this drug.
Patients taking TOBRAMYCIN AND DEXAMETHASONE who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is a less commonly reported adverse event for TOBRAMYCIN AND DEXAMETHASONE, but still significant enough to appear in the safety profile.
In addition to ocular hyperaemia, the following adverse reactions have been reported for TOBRAMYCIN AND DEXAMETHASONE:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 165 FDA reports for TOBRAMYCIN AND DEXAMETHASONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 2.4% of all adverse event reports for TOBRAMYCIN AND DEXAMETHASONE, making it a notable side effect.
If you experience ocular hyperaemia while taking TOBRAMYCIN AND DEXAMETHASONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.